List of Revolution Medicines, Inc. patents

Patents where

Current Assignee

Name

‌

Revolution Medicines, Inc.

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10533016 Compounds that participate in cooperative binding and uses thereof	Patent 10533016 was granted and assigned to Revolution Medicines, Inc. on January, 2020 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	10533016	January 14, 2020
‌ US Patent 11059830 Compounds that participate in cooperative binding and uses thereof	Patent 11059830 was granted and assigned to Revolution Medicines, Inc. on July, 2021 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11059830	July 13, 2021
‌ US Patent 10466249 Methods and reagents for analyzing protein-protein interfaces	Patent 10466249 was granted and assigned to Revolution Medicines, Inc. on November, 2019 by the United States Patent and Trademark Office.	Warp Drive Bio	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	10466249	November 5, 2019
‌ US Patent 11608346 Ras inhibitors	Patent 11608346 was granted and assigned to Revolution Medicines, Inc. on March, 2023 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11608346	March 21, 2023
‌ US Patent 11685749 C26-linked rapamycin analogs as mTOR inhibitors	Patent 11685749 was granted and assigned to Revolution Medicines, Inc. on June, 2023 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11685749	June 27, 2023
‌ US Patent 10980889 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors	Patent 10980889 was granted and assigned to Revolution Medicines, Inc. on April, 2021 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	10980889	April 20, 2021
‌ US Patent 11596633 SHP2 inhibitor compositions and methods for treating cancer		‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11596633	March 7, 2023
‌ US Patent 10948495 Methods and reagents for analyzing protein-protein interfaces	Patent 10948495 was granted and assigned to Revolution Medicines, Inc. on March, 2021 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	10948495	March 16, 2021
‌ US Patent 11168102 Bicyclic heteroaryl compounds and uses thereof	Patent 11168102 was granted and assigned to Revolution Medicines, Inc. on November, 2021 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11168102	November 9, 2021
‌ US Patent 11690915 Ras inhibitors	Patent 11690915 was granted and assigned to Revolution Medicines, Inc. on July, 2023 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11690915	July 4, 2023
‌ US Patent 11364300 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors	Patent 11364300 was granted and assigned to Revolution Medicines, Inc. on June, 2022 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11364300	June 21, 2022
‌ US Patent 11566007 Ras inhibitors		‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11566007	January 31, 2023
‌ US Patent 10989710 Identifying new therapeutic agents	Patent 10989710 was granted and assigned to Revolution Medicines, Inc. on April, 2021 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	10989710	April 27, 2021
‌ US Patent 11634435 Polycyclic compounds as allosteric SHP2 inhibitors	Patent 11634435 was granted and assigned to Revolution Medicines, Inc. on April, 2023 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11634435	April 25, 2023
‌ US Patent 11644460 Identifying new therapeutic agents	Patent 11644460 was granted and assigned to Revolution Medicines, Inc. on May, 2023 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11644460	May 9, 2023
‌ US Patent 10590090 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors	Patent 10590090 was granted and assigned to Revolution Medicines, Inc. on March, 2020 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	10590090	March 17, 2020
‌ US Patent 11220501 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor	Patent 11220501 was granted and assigned to Revolution Medicines, Inc. on January, 2022 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11220501	January 11, 2022
‌ US Patent 11673901 Polycyclic compounds as allosteric SHP2 inhibitors		‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11673901	June 13, 2023
‌ US Patent 11987590 Compounds that participate in cooperative binding and uses thereof	Patent 11987590 was granted and assigned to Revolution Medicines, Inc. on May, 2024 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11987590	May 21, 2024
‌ US Patent 11673896 Pyridine compounds as allosteric SHP2 inhibitors		‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11673896	June 13, 2023
‌ US Patent 11661401 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors		‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11661401	May 30, 2023
‌ US Patent 11702411 Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors		‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11702411	July 18, 2023
‌ US Patent 11952352 Ras inhibitors	Patent 11952352 was granted and assigned to Revolution Medicines, Inc. on April, 2024 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	11952352	April 9, 2024
‌ US Patent 12121522 Methods of treating cancer with an mTOR inhibitor	Patent 12121522 was granted and assigned to Revolution Medicines, Inc. on October, 2024 by the United States Patent and Trademark Office.	‌ Revolution Medicines, Inc.	‌ Revolution Medicines, Inc.	United States Patent and Trademark Office	12121522	October 22, 2024

24 results

0 selected

24 results

0 selected